Cranial Electrotherapy Stimulation for the Treatment of Major Depressive Disorder in Adults

NACompletedINTERVENTIONAL
Enrollment

255

Participants

Timeline

Start Date

April 28, 2022

Primary Completion Date

September 30, 2022

Study Completion Date

October 24, 2022

Conditions
Major Depressive Disorder
Interventions
DEVICE

Fisher Wallace Cranial Electrotherapy Stimulator (Active Device)

The indicated use in adults (ages 21-65 years) is for 20 minutes twice daily, upon waking for the day and at bedtime. The treatment period of the intervention will have a duration of four weeks.

DEVICE

Fisher Wallace Cranial Electrotherapy Stimulator (Placebo Device)

The placebo device is designed to provide exactly the same patient experience as the active device; however, the placebo device will not deliver the same frequencies as the active device. The placebo device will provide no therapeutic benefit.

Trial Locations (1)

10023

New York Neuromodulation Medical, PLLC, New York

All Listed Sponsors
collaborator

NAMSA

OTHER

collaborator

Climb Technologies, Inc.

INDUSTRY

lead

Fisher Wallace Laboratories

INDUSTRY

NCT05384041 - Cranial Electrotherapy Stimulation for the Treatment of Major Depressive Disorder in Adults | Biotech Hunter | Biotech Hunter